Cargando…
A New Look at the Most Successful Prodrugs for Active Vitamin D (D Hormone): Alfacalcidol and Doxercalciferol
Alfacalcidol (1α-hydroxyvitamin D(3)) has been widely used since 1981 as a prodrug for calcitriol (1α,25-dihydroxyvitamin D(3)) in the treatment of hypocalcemia, chronic renal failure, hypoparathyroidism and osteoporosis. More recently, doxercalciferol (1α-hydroxyvitamin D(2)) has been used since 19...
Autor principal: | Kubodera, Noboru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254965/ https://www.ncbi.nlm.nih.gov/pubmed/19924035 http://dx.doi.org/10.3390/molecules14103869 |
Ejemplares similares
-
Eldecalcitol is more effective in promoting osteogenesis than alfacalcidol in Cyp27b1-knockout mice
por: Hirota, Yoshihisa, et al.
Publicado: (2018) -
Comparison of the Pharmacological Effects of Paricalcitol and Doxercalciferol on the Factors Involved in Mineral Homeostasis
por: Wu-Wong, J. Ruth, et al.
Publicado: (2010) -
Osteocytic Protein Expression Response to Doxercalciferol Therapy in Pediatric Dialysis Patients
por: Pereira, Renata C., et al.
Publicado: (2015) -
Alfacalcidol improves the growth velocity in children with vitamin D deficiency/insufficiency: A single center retrospective cohort study
por: Miyagaki, Satoshi, et al.
Publicado: (2021) -
Effects of activated vitamin D, alfacalcidol, and low-intensity aerobic exercise on osteopenia and muscle atrophy in type 2 diabetes mellitus model rats
por: Akagawa, Manabu, et al.
Publicado: (2018)